Tuesday, November 17, 2026
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Fiinews
No Result
View All Result
Home Exports

Approved: Gujarat facility’s new drug

Fiinews by Fiinews
September 15, 2018
in Exports, Health, Investment, Manufacturing
Reading Time: 2 mins read
A A
0
0
SHARES
14
VIEWS
LinkedinShare on Twitter

XELPROSTM to be commercialize in US

 

 

The US Food and Drug Administration (USFDA) has approved Sun Pharma Halol (Gujarat) facility’s New Drug Application (NDA) of XELPROSTM (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension.

Sun Pharma Halol is a subsidiary of Sun Pharmaceutical Industries.

Sun Pharma in-licensed XELPROSTM from SPARC in June 2015.

SPARC is also eligible for milestone payments and royalties on commercialization of XELPROSTM in the US.

XELPROSTM is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations. XELPROSTM is developed using SPARC’s proprietary Swollen Micelle Microemulsion (SMM) technology.

“As the only BAK-free version of latanoprost, XELPROSTM will be an important and alternative treatment option for individuals with open-angle glaucoma or ocular hypertension,” said Abhay Gandhi, CEO, North America, Sun Pharma.

“This approval, coming less than one month following the approval of CEQUA™ (cyclosporine ophthalmic solution) 0.09%, reaffirms the strength of Sun Pharma’s fast-growing Ophthalmics division and its commitment to serving the needs of patients with ocular disorders,” said Gandhi.

SPARC CEO Anil Raghavan said: “Approval of XELPROSTM by USFDA is a significant milestone for SPARC. It is also a validation of our SMM technology which helps to solubilize drugs that have limited or no solubility thus eliminating the need for benzalkonium chloride (BAK).”

In randomized, controlled clinical trials of patients with open-angle glaucoma or ocular hypertension with a mean baseline Intraocular pressure (IOP) of 23-26 mmHg, XELPROSTM lowered IOP by a mean of up to 6-8 mmHg.

XELPROSTM will be commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmic division of Sun Pharmaceutical Industries Ltd.’s wholly owned subsidiary. fiinews.com

Tags: Sun Pharmaceutic Industries
ShareTweetShare

Related Posts

PIB
Exports

Export: India-Thailand traded $21.49bn in FY25-26

by Fiinews
November 17, 2026
0
22

Thailand presented its “Co-Creation Co-Investment” approach in Nonthaburi The India-Thailand bilateral trade reached USD21.49 billion in FY 2025–26, registering a...

PIB
Exports

Export: India-Egypt set $12bn bilateral trade target

by Fiinews
November 17, 2026
0
18

Ministers discussed trade, supply chains and predictable trade pathways. Minister of Commerce and Industry Piyush Goyal and Dr Mohamed Farid...

Vikram Solar

Manufacture: TN facility to produce from Dec 2026

November 16, 2026
18
ISNT

Manufacture: Minister wants strengthened NDT ecosystem

November 17, 2026
17
Indian Business Porftal

Export: Sustain growth in shipments, says FIOE Chief

November 16, 2026
24
Singapore Exchange

Invest: UTI Nifty listed in Singapore

November 14, 2026
20
SBI YONO

Recent News

  • Market: HGS-Rackspace to grow in high-value GCCs
  • Tech: DataSwitch’s Mathi automates data mapping
  • Export: India-Thailand traded $21.49bn in FY25-26
  • Export: India-Egypt set $12bn bilateral trade target
  • Manufacture: TN facility to produce from Dec 2026

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY
  • About
  • Advertise
  • Careers
  • Contact us

© 2026 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEAN

© 2026 FIINEWS - Design and developed by 7clicksmedia.